FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101.”
NanoViricides, Inc. (NYSE: NNVC) a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that it has successfully completed genetic toxicology testing required to support the IND application for NV-HHV-101 moving towards human clinical trials.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
The biopharmaceutical industry is driven by multiple factors, all while rapidly evolving in the digital era. The need to engineer drugs to treat emerging diseases, an increase in the geriatric population and rare medical conditions all fall under this umbrella. Additionally, investments in the research and development within the field have resulted in several novel drugs for diseases that are both effective and affordable. Data published by IQVIA™ Institute for Human Data Science shows that global drug spending reached USD 1.2 Trillion in 2018 and an estimated USD 1.5 Trillion will be spent by 2023. The key drivers of growth during the next five years are expected to be the United States as well as various emerging markets, with expected 4-7% and 5-8% compound annual growth rates, respectively. Meanwhile, artificial intelligence is transforming the development of medicines, with expedited processes and a larger range of areas researched. Currently, the use of smart algorithms to analyze large complex datasets is most advanced in areas of clinical and pre-clinical research and has applications in assessing preclinical compounds, identifying potential targets based on real-world data, and in driving efficiencies in clinical development. As a result, the number of new products launched by biopharmaceuticals is expected to increase from an annual average of 46 in the past five years to an average of 54 through 2023.
A major segment of the biopharmaceutical industry is the antiviral drug market. Antiviral drugs are medicines that diminish the ability of flu viruses to reproduce. Overall, antiviral drugs were manufactured to help reduce the duration of flu symptoms in otherwise healthy children and adults and may reduce the severity of common flu symptoms. The drugs are suggested for both treatment and prevention of flu, while some may also reduce the risk of complications such as ear infections in children, respiratory complications requiring antibiotics, and hospitalization in adults. Viruses use the host’s cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated. Most antivirals are used for specific viral infections, while a broad-spectrum antiviral is effective against a wider range of viruses. Factors such as rising occurrences of viral infection, increased public awareness, a rise in healthcare expenditure and effective investments in R&D are expected to boost the global antiviral drug market growth. And according to a research report published by Reports and Data, the global antiviral drugs market was valued at USD 49.87 Billion in 2018 and is projected to reach USD 71.48 Billion by the year 2026 while rising at a CAGR of 4.6%.
For more information, please visit: NanoViricides, Inc.
For more corporate news on Cannabix Technologies Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.